Welcome to Sequence Card of Peptide


Details of CPPsite entry with Sequence RRRRRRRRR
Primary information
PEPTIDE SEQUENCERRRRRRRRR
CPPsite ID 2067, 2175, 2208, 2248, 2316, 2435, 2496, 2534, 2553, 2554, 2683, 2702, 2705, 2871, 2911, 2954, 3008, 1035, 1414, 1811, 1812, 1813, 1843,
PEPTIDE NAMER9, Arg9, R9, R9-PCP, R9, R9, Arg9, RVG-9LR, ST2-104, FITC-ST2-104, TMR-R9, R8-p27kip1C, R8-PAD, R9, F7, PolyR, R9, R9, R9, R9, R9, R9, R9
CHIRALITYL, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L, L
LINEAR/CYCLICLinear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear, Linear
SOURCESynthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic, Synthetic
CATEGORYCationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, NA, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic, Cationic
SUB CELLULAR LOCALIZATIONCytosol, Vesicles, NA, Cytoplasm and Nucleus, Cytoplasm, NA, NA, Cytoplasm and Nucleus, Vesicles, Vesicles, Cytoplasm, Cytosol, Cytosol, NA, NA, NA, NA, Cytoplasm and nucleus, Unknown, Vesicules, Vesicles and cytosol, Cytoplasm, Punctate distribution (vesicles)
N-TERMINAL MODIFICATIONFree, Conjugation with fluorescein, Free, Acetylation, Biotinylation, Acetylation, Conjugation with fluorescein, Conjugated with RVG, Free, Conjugation with FITC, Conjugation with TMR, NA, NA, Free, Free, Conjugation with 5(6)-Carboxyfluorescein, NA, Conjugation with fluorescein with 6-aminohexanoic acid (Ahx) spacer, Conjugation with fluorescein, Conjugation with rhodamine B, Conjugation with rhodamine B, Conjugation with rhodamine B, Conjugation with fluorescein
C-TERMINAL MODIFICATIONFree, Amidation, Free, Amidation, Amidation, Amidation, Amidation, Conjugation with siFITC complex, Conjugation with CBD3 peptide of CRMP2, Conjugation with CBD3 peptide of CRMP2, NA, Amidation, Amidation, Free, Free, Free, Amidation, Free, Amidation, Amidation, Amidation, Amidation, Free
CHEMICAL MODIFICATIONNA, NA, NA, ?, L-2-naphthylalanine,miniPEG, 8-amino-3,6-dioxaoctanoic acid, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA, NA
UPTAKE EFFICIENCYNA, NA, More efficient in provoking bud formation, Lower efficiency, Lower than penetratin and R6W3, NA, Lower uptake efficiency, Lower uptake efficiency than D form, Higher uptake efficiency, Higher uptake efficiency, NA, NA, NA, Higher than peptide 1, NA, High, NA, High (relative to Tat (49-57)), Unknown, Greater than r9, Greater than r9, Greater than r9, Unknown
PROPOSED UPTAKE MECHANISMNA, Non-endocytosis, Endocytosis, direct translocation or physical endocytosis, Endocytic pathway, Endocytic pathway, NA, Non endocytosis pathway, Receptor-mediated endocytosis, Macropinocytosis, clathrin- mediated endocytosis and caveolae/lipid-raft-mediated endocytosis, Macropinocytosis, clathrin- mediated endocytosis and caveolae/lipid-raft-mediated endocytosis, lipid raft dependent macropinocytosis, NA, NA, NA, NA, NA, Endocytosis, Probably non-endocytic pathway, Unknown, Unknown, Unknown, Unknown, Energy dependent endocytic pathway
INVITRO/INVIVOIn vitro, In vivo, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro and in vivo, In vitro and in vivo, In vitro, In vitro, In vitro, In vitro, In vitro, In vivo, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro, In vitro
CELL LINEA549, RBL-2H3 cells, CHO-K1, Standard and Annexin 2-GFP transfected MDCK cells, HEK293, HeLa, MCF-7, NIH 3T3, A549, Jurkat, H1650, and H1299 cells, CHO-K1 (WT) and xylose transferase- or GAG-deficient CHO-pgsA745 cells (GAGneg), HeLa, Rat basophilic leukemia RBL-2H3 cells and CHO-K1, Neuro2a, Jurkat cells, Brain lysates prepared from embryonic day 19 rats, Brain lysates prepared from embryonic day 19 rats, U251-MG, HeLa, HEK293 cells, LNZ308, K562 cells, Primary rat fibroblasts cells and U87 cells, HeLa, T98G glioma cells, HeLa, T98G glioma cells, U87MG cells, C166-eGFP cells, NA, HeLa cells, Jurkat, HeLa, HeLa, MC57, Jurkat, HeLa
In VIVO MODELNA, NA, NA, NA, NA, NA, NA, NA, Female Sprague Dawley rats, Female Sprague Dawley rats, NA, NA, NA, NA, NA, Adult zebrafish, NA, NA, NA, NA, NA, NA, NA
CARGONucleic acid (pDNA), Fluorophore (Fluorescein), Nanoparticle (PMS labelled with the fluorescent probe di-4-ANEPPDHQ), Peptide [PCP, miniPEG-DE(pCAP)LI-NH2], Biotin-gly4, Fluorophore (FITC), Fluorophore (Fluorescein), Nucleic acid (siRNA), Peptide [Ca2+ channel binding domain 9CBD3)], Peptide [Ca2+ channel binding domain 9CBD3)] and Fluorophore (FITC), Fluorophore (TMR), Peptide (cyclin-dependent kinase inhibitor), Peptide [(Proapoptotic domain (PAD)], Fluorophore (FITC), Nucleic acid (siRNA), Fluorophore (5-Carboxyfluorescein), Nucleic acid (SCO), Fluorophore (fluorescein), Fluorophore (fluorescein), Fluorophore (fluorescein), Fluorophore (fluorescein), Fluorophore (fluorescein), Fluorophore (fluorescein)
PMID23534410, 25016968, 24583633, 24896852, 25112713, 25056130, 25016968, 25544044, 23106100, 23106100, 22465335, 22486588, 22486588, 25562654, 25894337, 11087855, 19858187, 21867915, 21867915, 21867915, 12411431
PATENTUnknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, Unknown, WO 2011/020188 A1, Unknown, US 2014/0140929 A1, US 6593292, Unknown, Unknown, Unknown, Unknown, Unknown
Tertiary Structure
(Technique)		2067 (PEPstrMOD), 2175 (PEPstrMOD), 2208 (PEPstrMOD), 2248 (PEPstrMOD), 2316 (PEPstrMOD), 2435 (PEPstrMOD), 2496 (PEPstrMOD), 2534 (PEPstrMOD), 2553 (PEPstrMOD), 2554 (PEPstrMOD), 2683 (PEPstrMOD), 2702 (PEPstrMOD), 2705 (PEPstrMOD), 2871 (PEPstrMOD), 2911 (PEPstrMOD), 2954 (PEPstrMOD), 3008 (PEPstrMOD), 1035 (PEPstrMOD), 1414 (PEPstrMOD), 1811 (PEPstrMOD), 1812 (PEPstrMOD), 1813 (PEPstrMOD), 1843 (PEPstrMOD),